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Abstract
Pre-clinical studies of traumatic brain injury (TBI) show that glyburide reduces edema and hemorrhagic progression of
contusions. We conducted a small Phase II, three-institution, randomized placebo-controlled trial of subjects with TBI to assess
the safety and efficacy of intravenous (IV) glyburide. Twenty-eight subjects were randomized and underwent a 72-h infusion of
IV glyburide or placebo, beginning within 10 h of trauma. Of the 28 subjects, 25 had Glasgow Coma Scale (GCS) scores of 6–10,
and 14 had contusions. There were no differences in adverse events (AEs) or severe adverse events (ASEs) between groups. The
magnetic resonance imaging (MRI) percent change at 72–168 h from screening/baseline was compared between the glyburide
and placebo groups. Analysis of contusions (7 per group) showed that lesion volumes (hemorrhage plus edema) increased
1036% with placebo versus 136% with glyburide ( p= 0.15), and that hemorrhage volumes increased 11.6% with placebo but
decreased 29.6% with glyburide ( p= 0.62). Three diffusion MRI measures of edema were quantified: mean diffusivity (MD),
free water (FW), and tissue MD (MDt), corresponding to overall, extracellular, and intracellular water, respectively. The percent
change with time for each measure was compared in lesions (n= 14) versus uninjured white matter (n= 24) in subjects receiving
placebo (n= 20) or glyburide (n= 18). For placebo, the percent change in lesions for all three measures was significantly different
compared with uninjured white matter (analysis of variance [ANOVA], p< 0.02), consistent with worsening of edema in
untreated contusions. In contrast, for glyburide, the percent change in lesions for all three measures was not significantly different
compared with uninjured white matter. Further study of IV glyburide in contusion TBI is warranted.
Keywords: contusion; edema; glyburide; MRI; SUR1; TBI
Introduction
More than 2 million Americans suffer injury or death dueto traumatic brain injury (TBI) each year, with TBI being a
major contributing factor in over one-third of trauma-related
deaths.1 A significant proportion of brain trauma survivors expe-
rience long-term disability, resulting in large societal costs from
both direct care as well as from loss of productivity by previously
healthy individuals. However, despite decades of research, phar-
macological therapy for TBI remains confined to early seizure
prophylaxis and, possibly, barbiturates, based on a small trial
showing better intracranial pressure (ICP) control compared with
placebo.2 More than 30 controlled clinical trials of pharmacological
therapies, however, have failed to improve mortality or outcome
following TBI.3
TBI proceeds in two phases, an immediate primary injury to the
brain due to structural disruption at the time of impact, and delayed,
progressive injury that results from a variety of pathophysiological
processes collectively termed secondary injury, including in-
creasing edema and hemorrhagic progression of contusion.4–6 Re-
cent research indicates a previously undescribed basis for some
forms of post-traumatic secondary injury. Specifically, experi-
mental models of contusion TBI,7–9 as well as patient-derived
clinical samples,9,10 consistently demonstrate both upregulation
and pathological pairing of sulfonylurea receptor 1 (SUR1) with the
non-selective cation channel, transient receptor potential mela-
statin 4 (TRPM4), to form SUR1-TRPM4 channels in brain en-
dothelium, astrocytes, and macrophages following contusion TBI.
Several pre-clinical studies provide a rationale for targeting
SUR1 following contusion TBI. Inhibition of SUR1 using
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glyburide or gene suppression reduces hemorrhagic progression
and edema, and may be associated with functional improvements
after contusion TBI, findings confirmed by several independent
research groups.7–9,11 Similarly, glyburide reduces hemorrhagic
progression after contusion injury to the spinal cord.12,13 Further, in
patients with TBI, cerebrospinal fluid (CSF) levels of SUR1 may
act as a biomarker that predicts swelling and outcome.14 Also,
genetic studies of SUR1 and TRPM4 polymorphisms in TBI pa-
tients have identified several SUR1 and TRPM4 variants linked to
brain swelling or cerebral edema.15–17
Glyburide, a member of the sulfonylurea class of oral anti-
diabetic drugs, is a potent pharmacological inhibitor of SUR1-
TRPM4 channels.18 Recent clinical experience with intravenous
(IV) glyburide in the treatment of large hemispheric infarction in-
dicates that glyburide is well tolerated, without clinically signifi-
cant off-target effects aside from occasional but manageable
hypoglycemia.19,20 Clinical experience with glyburide treatment
for TBI is limited to two small randomized controlled trials that
used the oral form of the drug, and showed a probable benefit of
glyburide with regard to contusion expansion and neurological
outcome.21,22
Here, we undertook a small Phase II multi-institutional ran-
domized controlled trial to evaluate the safety and mitigation of
hemorrhagic progression and edema with IV glyburide following
TBI. Surrogate biomarkers derived from magnetic resonance im-
aging (MRI) were the primary outcome measures.
Methods
Study organization
This was a double-blind, randomized, placebo-controlled, Phase
II trial of IV glyburide in patients with TBI (ClinicalTrials.gov
identifier: NCT01454154). It was one of several clinical trials
within the Department of Defense INTRuST [Injury &Traumatic
Stress], Post-Traumatic Stress Disorder - Traumatic Brain Injury
Clinical Consortium, but was the only consortium study focused on
acute TBI. UCSD (University of California, San Diego) was the
INTRuST coordinating center, providing the informatics and
biostatistic scores. Remedy Pharmaceuticals, Inc. provided the
drug (IV glyburide; a.k.a. RP-1127 or BIIB-093) and placebo
(excipients) for the study, under an Investigational New Drug
Application from the U.S. Food and Drug Administration. The
study was supervised by the Institutional Review Boards of the
individual centers, UCSD, and the USAMRMC (U.S. Army
Medical Research and Materiel Command).
Analysis of the MRI data was conducted by the Psychiatry
Neuroimaging Laboratory at Brigham and Women’s Hospital,
Harvard Medical School, Department of Psychiatry, which was the
core imaging center for the INTRuST consortium. The lead clinical
center for this trial was UMSOM (University of Maryland School
of Medicine), which later was joined by two other centers, UCSD
and UPMC (University of Pittsburgh Medical Center), although
ultimately, 76% of the total randomized participants were enrolled
at UMSOM. The primary biostatistician (SJ) had full access to all
the clinical data in the study. The project principal investigator
(HME) had final responsibility for the decision to submit for pub-
lication.
Subject enrollment and randomization
The study protocol called for enrolling 100 participants into one
of two arms, IV glyburide or placebo, at a 1:1 ratio. However, the
coordinating center reduced the number of participating sites from
five to three, and the study was terminated after 29 subjects had
been randomized, 30 months after starting, due to slow enrollment
and completion of the allotted period of funding. All participants’
legally authorized representatives (LARs) provided written in-
formed consent at enrollment. Subjects were consented and en-
rolled into the study, but were not randomized until completion of
the T1-weighted (T1w) and diffusion tensor imaging (DTI) se-
quences of the baseline MRI. Randomization and infusion of drug
or placebo then proceeded, as long as infusion could be started
within 10 h of the trauma. Participants were randomly assigned to
receive IV glyburide or placebo in a 1:1 ratio from a centralized,
web-based randomization system (Interactive Web Randomization
System). At randomization, subjects were stratified on the basis of
their Glasgow Coma Scale (GCS) score (4–8 and 9–14) obtained
free of the effects of sedating and/or paralytic drugs, closest to the
time of randomization.
The major inclusion/exclusion criteria were age (18–75 years),
GCS score 4–14, start of infusion within the 10-h window, history
of treatment with sulfonylurea drugs, and perceived inability to
tolerate the initial MRI scan (full inclusion/exclusion criteria are
provided in Supplementary Appendix S1). The INTRuST coordi-
nating center (except for the Biostatistics Core), Remedy Phar-
maceuticals, the principal investigator, site investigators, patients,
imaging core, and outcomes personnel were blinded to treatment.
Treatments
The bolus and the infusion concentrations of glyburide were
both 5.3 lg/mL. Glyburide was infused IV as a loading dose,
0.13 mg over 2 min, then 0.16 mg/h for 6 h, and then 0.11 mg/h for
66 h (total daily dose on day 1 was 3.12 mg and on days 2 and 3 was
2.67 mg/day) versus placebo (similar in appearance to drug and at
the same rate). This dose was based on data from a Phase I drug
escalation safety study.23 The infusion protocol and 10-h window
were identical to that used in a Phase II trial of glyburide in large
hemispheric infarction.20 Drug vials, preparation bags, and tubing
were identical in appearance for both treatment groups. Con-
comitant treatments followed national practice guidelines for TBI
patients.24
Study outcome measures
The pre-specified primary efficacy objective was to assess
whether subjects treated with IV glyburide would show a decrease
in MRI-defined edema and/or hemorrhage, compared with placebo-
treated patients. The study protocol did not specify which specific
measure of edema and/or hemorrhage would be primary (see below
for the measures that were quantified). Efficacy outcome was as-
sessed using data from two sequential MRIs, a baseline MRI before
infusion of drug or placebo, and another MRI after completion of
infusion, specifically indexing water and blood. The interval be-
tween the baseline MR scan and the second scan was initially
specified as 72 – 12 h. However, very early in the study, we realized
that this was not possible in some subjects, when the second scan
had to be delayed mainly due to ICP elevations above guideline
levels when participants were positioned flat for scanning. The
protocol then was revised to extend the interval to 168 h (7 days).
The number of patients scanned within the 72-h window, the 168-h
window, and beyond 168 h are reported separately.
A pre-specified secondary efficacy outcome was the Glasgow
Outcome Scale Extended (GOS-E) at 90 days.
The primary safety objective was to assess the safety (the inci-
dence of mortality, adverse events [AEs], and serious adverse events
[SAEs]) and tolerability of IV glyburide compared with placebo in
subjects with severe, moderate, or complicated mild TBI.
MRI data acquisition
MRI scans were acquired at each site on a 1.5T scanner.
At UMSOM, two identical Siemens Avanto scanners were used
186 EISENBERG ET AL.
(baseline and follow-up scans for each subject were always on the
same scanner). At the UCSD and UPMC sites, a single 1.5 Signa
GE scanner was used. One single phantom was used to standardize
all scanners at all sites. Also, at each site, patients were always
scanned using the same scanner.
The MRI acquisition was set to minimize differences between
vendors and included anatomical sequences: high resolution
(1 · 1 · 1 mm3) T1w (Siemens: magnetization-prepared rapid
gradient-echo [MPRAGE], inversion time of 1100 msec, flip angle
7 degrees; GE: spoiled gradient recalled [SPGR], inversion time of
600 msec, flip angle 10 degrees], high resolution T2, proton density
(Dual echo, echo time [TE]: 12 msec and 100 msec; 1· 1· 1 mm3),
and a clinical fluid-attenuated inversion recovery (FLAIR) se-
quence (1.3 mm· 1 mm· 5 mm; inversion time: 2500 msec). Two
additional scans of interest were diffusion MRI and susceptibility-
weighted imaging (SWI). The diffusion MRI scan included a multi-
shell design with 46 unique gradient orientations and a total of 66
volumes spread over 5 nested b-shells of 1 · 0, 3· 50, 6· 250,
10 · 500, 30 · 900, and 16· 1400 sec/mm2, and the following pa-
rameters: 2.5 mm isotropic, 66 slices (Siemens: repetition time
[TR]/TE 8500/85 msec; GE: TR/TE 9550 msec/min). The SWI
scan was a 3D gradient-echo scan (1 mm· 1 mm · 1.5 mm, TR/TE
50/40 msec, flip angle: 15 degrees) outputting the magnitude and
phase images.
Regions of interest
Three regions of interest (ROIs) were analyzed for volumetric
changes: the total lesion volume (blood plus edema) (n = 15), blood
alone (n = 14), and the total brain volume (n= 24). Four additional
ROIs were analyzed for changes in edema: uninjured white matter
(n = 24); lesions, that is, contusions (n= 14); all quadrants in a
coronal slice (four per subject; n= 96); and the maximally affected
quadrant (one per subject; n= 24). For lesion ROIs (blood plus
edema), we aligned images from computed tomography (CT) and
MRI. Lesion volumes were calculated by electronically tracing the
areas of the lesion on sequential slices. Edema was identified pre-
dominantly based on hyperintensities in the FLAIR and T2 se-
quences (Fig. 1A). Hemorrhage was identified based on
hypointensities in the SWI contrast (following phase enhance-
ment25) and blood densities on CT (Fig. 2A,B). The final lesion
ROIs were reviewed and modified by a neurosurgeon, a neurora-
diologist, and a researcher specializing in image analysis, blinded
to treatment arm. Lesions were excluded if they were outside brain
(e.g., subarachnoid and extra-axial and interventricular hemor-
rhages were excluded). Apparent lesions also were excluded if they
were directly related to a treatment that took place between the two
MRIs (e.g., surgery or insertion of an intraventricular catheter).
For uninjured white matter ROIs, which were intended as an
exploratory approach to identify global effects of the drug, we used
expectation-maximization (EM) segmentation of the T1w image
(FAST; FSL) (Fig. 1C). The white matter segment was eroded by
one voxel to avoid partial volume voxels, and we excluded all
lesions that were defined in the previous approach (the lesion
segments here were first dilated by one voxel).
For all quadrant ROIs, which also were intended as an explor-
atory approach to identify global effects of the drug, each quadrant
within a coronal brain slice was studied separately, whether or not a
lesion was present (Fig. 1B).
For the maximally affected quadrant, the single quadrant of a
coronal brain slice with the maximal change in edema parameters
for each subject was used.
MRI data analysis
All evaluators and those involved in management of subjects
including the PI (HME) were blinded to treatment arm and other
clinical or demographic information. All imaging data were sub-
jected to visual quality control to exclude images with severe
motion or other artifacts. The diffusion data were manually masked
to exclude non-brain areas. The anatomical images were co-
registered using rigid transformations (within time-points) and af-
fine transformations (between time-points). In addition, the ana-
tomical images were manually masked based on the T1w image, all
by investigators blind to treatment arm.
The diffusion MRI data were pre-processed using motion and
eddy correction applied by means of affine transformations
(FLIRT; FSL). The aligned images then were analyzed using the
DTI model,26,27 and the free-water imaging model,28,29 yielding
voxel-wise maps of DTI measures and free-water imaging
measures.
Three MRI diffusion measures were used to assess edema: (1)
mean diffusivity (MD); (2) the volume fraction of free water (FW);
and (3) tissue mean diffusivity (MDt). MD was derived from the
DTI, whereas FW and MDt were derived from the free-water im-
aging model. MD provides an overall measure of diffusivity; as
FIG. 1. Representative FLAIR and T1w images illustrating
ROIs that were studied. (A,B) Axial slices of FLAIR images on
day 0 and day 4 showing lesion ROIs (A) and quadrant ROIs (B);
to compensate for different gantry angles on different days, the
slices illustrated are the first full slice above the right orbital roof.
(C) Sagittal slices of T1w images on day 0 and day 4 showing
uninjured white matter. All images are from patient 14, who re-
ceived IV glyburide. FLAIR, fluid-attenuated inversion recovery;
IV, intravenous; ROI, region of interest; T1w, T1-weighted.
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water molecules move faster on average, the MD measure is higher.
FW and MDt measures further deconstruct the signal contribution
into extracellular (FW) and intracellular (MDt) water. The free-
water model separates the signal into water molecules that are free
to diffuse in the extracellular space (i.e., diffusing at 3· 10–3 mm2/
sec), and all remaining molecules that are restricted or hindered by
membranes and other tissue-related obstacles.
Higher fractions of extracellular space, which are expected in
vasogenic edema, would increase FW. Changes in the geometry,
and hence the speed of water molecules in proximity to tissue,
would affect the MDt, whereas less restricted motion would in-
crease MDt. On the other hand, cellular swelling (i.e., cytotoxic
edema) would decrease the non-restricted space, decreasing FW,
and modifying MDt. Values for MD, FW, and MDt were averaged
for each of the four ROIs described above. Because edema was an
important end-point due to the expected drug mechanism, and
because the ROIs were large, we did not consider anisotropic
measures such as fractional anisotropy or radial or axial diffusiv-
ities. Hemorrhage was assessed by the number of positive voxels on
SWI within the boundaries of the lesion ROIs.
Sample size calculation
A sample size calculation was performed based on a two-sided,
two-sample t test to compare published differences in absolute
values in apparent diffusion coefficient (ADC) in TBI patients
relative to normal subjects, and was computed using standardized
effect sizes. With an anticipated sample size of 100 participants
(equal allocation between active and placebo arms), the study
would have 80% power to detect a 60% standardized change in
treatment arms, assuming 10% attrition over 72 h and a= 0.05.
Statistical analysis plan
Analyses were to incorporate the intent-to-treat principle,
namely, all randomized participants would be included in the
analysis according to their treatment assigned at randomization.
The safety analysis was to be performed on the safety population
only, that is, all those who were exposed to any study drug. No
adjustments for multiple comparisons were to be made for sec-
ondary analyses, and a p-value of 0.05 was be considered statisti-
cally significant. The final statistical analysis plan was to be
determined by the INTRuST Biostatistics Core within 6 months
before study end.
Statistical analysis
All MRI measures were evaluated as the ‘‘percent change’’ of
the second MRI compared with the screening/baseline MRI, before
infusion of study drug or placebo. Summary measures (mean,
standard deviation, median, first and third quartiles, minimum and
maximum values) described the data overall and by study arm for
each outcome at screening/baseline and at the second scan. Sum-
mary measures were produced overall and by study arm for each
outcome for the percent change from screening/baseline to the
second scan. The primary analysis was based on a two-sided, two-
sample Wilcoxon rank sum test to compare the glyburide and
placebo arms. A secondary analysis of the three MRI measures of
edema (MD, FW and MDt) was based on an analysis of variance
(ANOVA) to compare four groups: lesions versus uninjured white
matter, in the glyburide and placebo arms. Safety data were sum-
marized overall and by treatment groups. Fisher’s exact test was
used to compare the number of subjects between groups who ex-
perienced any adverse events (AEs). Statistical analyses were
performed in R version 3.1.1. (www.r-project.org) or GraphPad
Prism version 8.
Results
General
In all, 1483 potentially qualified participants were screened at
the three centers, the largest number at UMSOM (924). Of those
screened, 38 were consented. The most frequent reasons not to
consent included: GCS score out of range (529), perceived inade-
quate time from admission to hospital to start of infusion (202), and
LAR not available (95). Other less common reasons included an
anticoagulant medication and elevated blood alcohol (see Supple-
mentary Fig. S1). Of the 38 consented, 9 could not be randomized
(5 could not complete the baseline MRI and 4 could not start the
infusion on time). Of the 29 subjects randomized (15 in the gly-
buride group, 14 in the placebo group), 1 randomized to the IV
glyburide arm did not receive the drug because of withdrawal of
consent. Two subjects were randomized or infused incorrectly.
Errors included randomization or infusion outside of the time
window, and protocol-unspecified stopping and restarting of infu-
sion. These protocol violations occurred early in the trial. These
subjects were included in the efficacy and safety analysis, due to the
intent-to-treat design. However, data from these subjects were not
included when reporting details about infusion and completing
infusion according to protocol. Thus, 28 participants completed the
acute phase of the study and reached their primary end-points. All
26 uncensored participants had the 72-h infusion of the study drug
beginning within 10 h of injury.
FIG. 2. Representative CT and SW images illustrating hemor-
rhages. (A,B) Axial slices of CT (A) and SW (B) images on day 0
and day 4 showing hemorrhages; to compensate for different
gantry angles on different days, the slices illustrated are the first
full slice above the right orbital roof. All images are from patient
14, who received IV glyburide. CT, computed tomography; IV,
intravenous; SW, susceptibility-weighted.
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Baseline characteristics
Seventy-two percent of the randomized participants were male,
10 in the placebo arm and 11 in the glyburide arm, and 28% were
female (4 in each arm). The median age in the placebo arm was 23
years (66 maximum) and it was 22 years in the glyburide arm
(60 maximum). ICP was monitored at randomization in 20 par-
ticipants. The median ICP at randomization was 14 mm Hg in the
placebo arm (maximum 19) and 11 mm Hg in the glyburide arm
(maximum 16). Randomization median PaO2 and mean arterial
pressure were virtually identical in the two arms and were within
normal ranges. Randomization median blood glucose was
138 mg/dL (185 maximum) in the placebo arm and 139mg/dL
(maximum 248) in the glyburide arm.
GCS scores obtained at the time closest to randomization are
shown in Table 1. No patient with a GCS score >11 met require-
ments for randomization. Twenty-five of the 29 randomized par-
ticipants had GCS scores 6–10, 86% of the cohort. A GCS score of
7 was the most common score. In this regard, the cohort was in the
range of lower-moderate to upper-severe injury.
Laboratory findings
Routine blood chemistries were collected at screening, baseline,
and at days 1, 2, 3, and 4. There were no group differences with
regard to most of these measures. Glucose was monitored; blood
samples were taken hourly for the first 24 h, then every 4 h for the
next 24 h. Hypoglycemia was managed by a detailed protocol (see
Supplementary Appendix S2), which specified glucose levels, and
specified administering glucose and, if necessary, reducing or
suspending the infusion of the study drug (investigator blind to
treatment arm). Two participants had glucose levels <55 mg/dL at
one time-point. None of the 26 uncensored subjects had suspension
of drug infusion; all cases of hypoglycemia were managed by in-
fusion of glucose. The glucose data were analyzed using an area
under the curve (AUC) approach by 24 h. No significant difference
between groups was found. Hourly collection of vital signs, which
included blood pressure and heart rate, were also analyzed using
AUC by 24 h, with no significant differences found between
groups.
Adverse events
There were no deaths. Three patients (2 in the glyburide arm, 1 in
the placebo arm) had transient neurological worsening (decreased
GCS score of 2 points in 2 consecutive h and/or a newly dilated
pupil). There were no significant differences in the frequencies of
defined AEs between the two treatment groups (glyburide, 87% vs.
placebo, 100%; p = 0.48), nor was there a significant difference
with regard to severe adverse events (SAEs) (glyburide, 20% vs.
placebo, 14%; p= 0.99). Overall, there were 7 SAEs in 5 partici-
pants (Table 2).
MRI analysis—general
Of the 26 uncensored participants, all had a 72-h drug infusion
beginning within 10 h of trauma. Of the 28 participants randomized
and infused, 17 had their second scan within the initially proposed
72– 12-h window (drug 8, placebo 9), whereas 7 additional par-
ticipants had their second scan at or before 168 h (drug 3, placebo
4). Four others did not have a second scan within the 168-h window.
For the 14 participants with identified lesions (contusions), 10
participants had their second scan within the 72 – 12-h interval
(drug 5, placebo 5). The other 4 had their second scan at or before
168 h (drug 2, placebo 2). The distribution of randomization GCS
for the lesion ROI cohort is shown in Table 3.
MRI analysis—volumetric changes
Three ROIs were analyzed for volumetric changes: the total
lesion volume (blood plus edema), the volume of blood alone, and
the total brain volume (Table 4). Lesion volumes increased in both
treatment arms, but more so in the placebo arm. The volume of
blood in lesions increased in the placebo arm, whereas it decreased
in the glyburide arm (Fig. 2A,B). Neither of these differences
reached statistical significance. Changes in total brain volume were
small.
MRI analysis—measures of edema in four ROIs
The percent change from screening/baseline to the second scan
was analyzed for three measures of edema: MD (overall water), FW
(extracellular water) and MDt (intracellular water); these three
measures of edema were evaluated in four ROIs: uninjured white
matter, lesions, all quadrants, and the maximally affected quadrant
Table 1. Glasgow Coma Scale Score at Randomization
GCS Placebo Glyburide Total
4 0 (0%) 1 (6.7%) 1 (3.4%)
5 1 (7.1%) 1 (6.7%) 2 (6.9%)
6 2 (14.3%) 2 (13.3%) 4 (13.8%)
7 5 (35.7%) 5 (33.3%) 10 (34.5%)
8 2 (14.3%) 1 (6.7%) 3 (10.3%) 25 (86%)
9 1 (7.1%) 3 (20%) 4 (13.8%)
10 2 (14.3%) 2 (13.3%) 4 (13.8%)
11 1 (7.1%) 0 (0%) 1 (3.5%)
Total 14 (100%) 15 (100%) 29 (100%)
GSC, Glasgow Coma Scale.
Table 2. Serious Adverse Events (SAEs)
by Treatment Arm
Glyburide Placebo Total
Not related 3 (75%) 3 (100%) 6 (85.7%)
Unlikely 0 (0%) 0 (0%) 0 (0%)
Possible 0 (0%) 0 (0%) 0 (0%)
Probable 1 (25%) 0 (0%) 1 (14.3%)
Definite 0 (0%) 0 (0%) 0 (0%)
Total 4 (100%) 3 (100%) 7 (100%)
Table 3. Randomization GCS for Subjects
with Lesions (contusions)
GCS Glyburide Placebo Total
5 1 (14.3%) 0 (0%) 1 (7.1%)
6 1 (14.3%) 1 (14.3%) 2 (14.3%)
7 3 (42.9%) 2 (28.6%) 5 (35.7%)
8 0 (0%) 1 (14.3%) 1 (7.1%)
9 1 (14.3%) 1 (14.3%) 2 (14.3%)
10 1 (14.3%) 2 (28.6%) 3 (21.4%)
Total 7 (100%) 7 (100%) 14 (100%)
GCS, Glasgow Coma Scale; ROI, region of interest.
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in each subject (Table 5). Overall, the greatest differences between
treatment arms was found in lesion ROIs, in which all three mea-
sures of edema showed larger percent increases with placebo
compared with glyburide. In pairwise comparisons, only MDt in
the all-quadrants ROI reached statistical significance between
glyburide and placebo.
We performed a secondary analysis of the three measures of
edema, comparing changes in uninjured white matter and in lesions
in the two treatment arms (Fig. 3). ANOVA showed a significant
difference in all three measures of edema ( p < 0.02). Post hoc
comparisons showed no significant effect of drug in uninjured
white matter or in lesions, as in the primary pairwise analyses.
However, comparing the placebo arms, there was a significant
difference between uninjured white matter and lesions in all three
measures of edema, consistent with worsening of edema with time
in untreated contusions. By contrast, comparing the glyburide arms,
there was no significant difference between uninjured white matter
and lesions for any of the three measures of edema.
Clinical outcomes
As judged by the GOS-E at 90 days, half of the patients in the
glyburide group made a good recovery, although 3 were catego-
rized as either vegetative or severely disabled (Table 6). Dichot-
omizing for GOS-E £4 versus >4 at 90 days showed no significant
difference between groups ( p= 0.32).
Discussion
We sought to assess two principal aspects of glyburide therapy in
TBI, namely whether glyburide can be safely administered early
after moderate-to-severe TBI, and whether glyburide ameliorates
secondary injury, specifically, the development of edema and the
delayed expansion of hemorrhage.
The severity of injury in the subjects reported here—moderate
(GCS 9–12) and the better end of severe (GCS 6–8) injury, with a
few sustaining severe polytrauma—was likely influenced by mul-
tiple factors, including the time for transfer from the scene, resus-
citation, obtaining consent from a LAR, and the requirement for
early MRI, which together caused many screened patients not to be
randomized. No patient with GCS >11 met requirements for ran-
domization, which may reflect the fact that patients with lesser
injuries are unlikely to be transferred to the R. Adams Cowley
Shock Trauma Center at the University of Maryland, where most
patients were recruited.
The cohorts, glyburide and placebo, reported here were small,
but they were well balanced with regard to important predictors,
including randomization GCS, age, and ICP in the overall, as well
as in the lesion ROI subset. They also were balanced as to the time
the second MRI was acquired, at 72 h or later. There were no im-
portant differences in the baseline physiological data of blood
pressure, glucose, or ICP as analyzed by AUC.
No safety concerns were reported. Only two subjects required
correction of asymptomatic hypoglycemia by infusion of glucose,
and drug infusion did not have to be stopped in any subject. With
TBI, hypoglycemia may be detrimental to neurological recovery
due to increased demands of brain energy metabolism.30 However,
patients treated with glyburide demonstrated glucose levels com-
parable to those of controls. Studies of IV glyburide in ischemic
stroke19,20 have found a similar absence of symptomatic hypogly-
cemia. This small trial indicates that early use of IV glyburide in
moderate-to-severe TBI may be safe, provided that blood glucose is
closely monitored and properly managed.
MRI parameters for edema and blood indicated that glyburide
may be useful in contusion TBI. Statistical significance was elusive
in pairwise comparisons, likely due to the small cohorts, especially
with contusions (7 per group), combined with the large variance
that is typical in studies of TBI. Nevertheless, interesting obser-
vations were made. The increase in lesion volume (hemorrhage
plus edema) over time was many-fold greater in placebo- compared
with glyburide-treated subjects, and the blood volume increased in
placebo-treated subjects, whereas it decreased in glyburide-treated
subjects. Notably, an analysis comparing uninjured white matter
versus lesions showed that in placebo-treated subjects, measures of
edema increased significantly with time, whereas they did not in
glyburide-treated subjects. Together, our findings provide prelim-
inary evidence of a favorable effect of glyburide in human TBI that
mirrors pre-clinical findings.7–9 The absence of a significant effect
Table 4. Percent Changes in Three Volumes
That Were Analyzed
Volume Mean SD N P
Total lesion
(blood + edema)
G 136.06 195.62 7 0.15
P 1036.29 1963.28 8
Blood alone G –29.55 36.75 7 0.62
P 11.64 91.37 7
Total brain G 2.01 9.02 11 0.13
P 2.16 3.26 13
G, glyburide; P, placebo; SD, standard deviation.
Table 5. Percent Changes in Three MRI Measures
of Edema in Four Regions of Interest
Region of
interest
Measure
of edema Treatment Mean SD N P
Uninjured
white matter
MD G 3.95 6.40 11 0.49
P 1.55 3.14 13
FW G 11.74 17.36 11 0.28
P 3.24 7.84 13
MDt G 1.70 3.66 11 0.84
P 0.93 2.05 13
Lesions MD G 6.27 9.21 7 0.26
P 22.04 23.94 7
FW G 10.73 13.99 7 0.32
P 44.96 57.68 7
MDt G 2.41 6.67 7 0.21
P 9.66 8.31 7
All quadrants MD G 3.20 5.94 44 0.48
P 3.71 5.13 52
FW G 12.44 15.25 44 0.42
P 10.20 15.80 52
MDt G 0.68 3.10 44 0.05
P 1.33 2.04 52
Maximally
affected
quadrant
MD G 6.37 6.96 11 0.95
P 6.81 7.27 13
FW G 20.29 16.95 11 0.49
P 16.98 22.69 13
MDt G 2.36 3.53 11 0.36
P 2.90 2.33 13
FW, free water; G, glyburide; MD, mean diffusivity; MDt, tissue mean
diffusivity; MRI, magnetic resonance imaging; P, placebo; SD, standard
deviation.
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on clinical outcome was not unexpected, given the small sample
size and the potential for multiple confounders.
Given the pre-clinical evidence showing an effect of glyburide
on hemorrhagic progression of contusion,7–9 we hypothesized that
glyburide administration would reduce hemorrhagic expansion. In
the literature on contusion TBI, hemorrhagic expansion is observed
in *50% of cases5,6 whereas in this small study, no subjects ex-
hibited frank hemorrhagic expansion. Importantly, albeit unex-
pectedly, glyburide-treated subjects demonstrated a marked
decrease in hemorrhage volume, whereas a small increase was
observed with placebo. The observed decrease in hemorrhage
volume is not readily accounted for solely by a reduction in ex-
pansion. Although speculative, the observed reduction may derive
from an effect of glyburide on macrophages, which play a key role
in hemorrhage resorption.31–33 Macrophages that are present within
hemorrhagic contusions are known to upregulate SUR1-TRPM4,9
and macrophage phagocytic activity is reportedly enhanced by
glyburide.34,35
There are several limitations of this trial. First, the trial included
only 28 participants. Second, the study population was heteroge-
neous, in that only half (14/28) had contusions, the type of injury in
which an effect of glyburide may be the most anticipated. Third, the
timing of follow-up MRI was heterogeneous, potentially limiting
the interpretation of the effects of IV glyburide. Fourth, the drug
FIG. 3. Measures of edema in lesions versus uninjured white matter. Percent changes in MD, FW, and MDt were compared in
uninjured WM and in lesions for the two treatment arms. All three measures of edema showed a significant difference (ANOVA,
p < 0.02). For each measure of edema, comparing the two placebo arms, there was a significant difference between uninjured WM and
lesions, whereas comparing the two glyburide arms, there was no significant difference between uninjured WM and lesions. ANOVA,
analysis of variance; FW, free water; MD, mean diffusivity; MDt, tissue mean diffusivity; WM, white matter.
Table 6. GOS-E at 90 Days
Glyburide Placebo
Dead 0 (0%) 0 (0%)
Vegetative state (VS) 2 (16.67%) 0 (0%)
Lower severe disability (Lower SD) 1 (8.33%) 0 (0%)
Upper severe disability 0 (0%) 1 (7.69%)
Lower moderate disability (Lower MD) 2 (16.67%) 1 (7.69%)
Upper moderate disability (Upper MD) 1 (8.33%) 7 (53.85%)
Lower good recovery (Lower GR) 3 (25%) 4 (30.77%)
Upper good recovery (Upper GR) 3 (25%) 0 (0%)
GOS-E, Glasgow Outcome Scale Extended.
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was started nearly 10 h after trauma. In light of the time and efficacy
interaction of glyburide in pre-clinical TBI studies,7 this compar-
atively late administration may have attenuated the observed effect
size. Fifth and finally, it is possible that a higher dose of IV gly-
buride than that used in this study might have led to a more robust
clinical effect. Further study is needed to confirm the results re-
ported here that glyburide may ameliorate both edema and hem-
orrhagic progression in moderate-to-severe contusion TBI.
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